Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Yersinia pestis vaccine (Primary) ; CpG 1018
- Indications Plague; Pneumonic plague
- Focus Pharmacodynamics
- Sponsors Dynavax Technologies
- 13 Jan 2025 According to a Dynavax Europe media release, Dynavax and the DoD executed a new agreement for approximately $30 million through the first half of 2027 to support additional Phase 2 clinical and manufacturing activities
- 06 Aug 2024 According to a Dynavax Europe media release, company anticipates providing a program update, based on results from this study and pre-clinical study.
- 06 Aug 2024 According to a Dynavax Europe media release, this trial is being conducted in collaboration and fully funded by, the U.S. Department of Defense.